Project Grant R21AI190273
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$428K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
The University of North Carolina at Chapel Hill was awarded a $427,625 Project Grant by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to study the factors contributing to treatment failure of hypervirulent Klebsiella pneumoniae liver abscesses. The research aims to: 1) use quantitative and imaging mass spectrometry to visualize antibiotic distribution and the role of antibiotic-tolerant cells in treatment failure, and 2) employ...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $249,000.00 to the Regents of the University of Minnesota to define the mechanisms by which macrophages restrict the bacterium Klebsiella pneumoniae (KP) during bloodstream infections (bacteremia). The research aims to 1) understand how splenic macrophages restrict KP during bacteremia, 2) elucidate host pathways of KP...
The federal Project Grant award R21AI190454 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Illinois. The $456,911 award, effective July 1, 2025 through June 30, 2027, supports research to develop innovative antibiotic combination therapies for treating hypervirulent, multidrug-resistant Klebsiella pneumoniae infections. Key objectives include elucidating the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research provides $259,461 to The Methodist Hospital Research Institute to investigate the genomic factors and clinical impact associated with non-carbapenemase producing carbapenem-resistant Klebsiella pneumoniae (NCP-KPN) infections. The key objectives are to characterize a large international collection of NCP-KPN isolates using whole genome...
This federal Project Grant award of $254,478 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify mechanisms of resistance to pathogen-specific antibacterial antisense compounds and develop strategies to overcome them. The award recipient, The University of Texas Southwestern Medical Center, will investigate resistance to these novel antibacterial compounds called...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $222,852 to support research into the regulation of virulence factors in the pathogenic bacterium Clostridioides difficile. The primary objective is to identify and annotate Rho, NusA, and NusG dependent transcriptional terminators in C. difficile to understand how these regulatory factors influence the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $212,169 to The Johns Hopkins University to advance mentorship and research capabilities related to combating antimicrobial resistant (AMR) infections. The award will enable the principal investigator to enhance their expertise in constructing site-directed mutants of key β-lactamase enzymes and integrating...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $125,619 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Santa Cruz (UCSC) to investigate how the bacterial pathogen Helicobacter pylori utilizes ribosomal silencing to maintain chronic gastric infections. The research aims to expand understanding of how H. pylori regulates its ribosome population under growth-limiting conditions, such as biofilms,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop new antimicrobial agents and combination therapies to combat the growing threat of Gram-negative bacterial pathogens, specifically carbapenem-resistant Acinetobacter baumannii (CRAB) and Klebsiella pneumoniae (CRKP). The $2,308,174 award, with a performance period from August 2024 to May 2029, will fund three...
This Project Grant award of $747,763 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of small molecule inhibitors of the LPXH enzyme as novel antibiotics to treat multidrug-resistant Enterobacterales infections. The goal is to design and synthesize potent LPXH inhibitors with optimal drug-like properties, and demonstrate the safety and efficacy of a lead LPXH inhibitor candidate in a murine sepsis...